Global Mycosis Fungoides Treatment Market Report 2024

The mycosis fungoides treatment market size has grown strongly in recent years. It will grow from $0.91 billion in 2023 to $0.97 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth observed in the historic period can be attributed to several factors, including increased incidences of immune system dysfunction leading to a higher demand for effective therapeutics, widespread adoption of phototherapy as a treatment modality, increased utilization of radiation therapy, and the growing popularity of supportive care measures aimed at managing symptoms and improving patient outcomes.

The mycosis fungoides treatment market size is expected to see strong growth in the next few years. It will grow to $1.26 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The anticipated growth in the forecast period is expected to be driven by advancements in healthcare infrastructure, a growing patient population, and an increase in the prevalence of mycosis fungoides possibly due to unhygienic lifestyles. Major trends projected for this period encompass technological advancements in treatment options related to chemotherapy, an uptick in the demand for monoclonal antibodies as first-line therapy, the introduction of new advanced products into the market, and an increasing focus on investment in research and development efforts.

The increasing incidence of lymphoma cancer is expected to drive the expansion of the mycosis fungoides treatment market in the future. Lymphoma, a cancer affecting the lymphatic system comprising lymph nodes, spleen, thymus gland, and bone marrow, is on the rise due to various factors such as environmental exposures, viral infections, an aging population, and lifestyle choices. Mycosis fungoides treatments, including topical corticosteroids, phototherapy, and systemic therapies, are utilized in managing cutaneous T-cell lymphomas to control skin lesions, alleviate symptoms, and manage disease progression in lymphoma patients. For example, in January 2024, according to the American Cancer Society, non-Hodgkin lymphoma (NHL) ranked among the most prevalent cancers in the United States, constituting about 4% of all cancer cases. It was estimated that around 80,620 individuals (44,590 males and 36,030 females) would be diagnosed with NHL, with approximately 20,140 people (11,780 males and 8,360 females) succumbing to this cancer in 2024. Hence, the increasing incidence of lymphoma cancer is fueling the growth of the mycosis fungoides treatment market.

Key players in the mycosis fungoides treatment market are focusing on developing advanced therapies such as CAR T cell therapy to enhance treatment efficacy and specificity. CAR T cell therapy, a form of immunotherapy, involves genetically modifying a patient's T cells to better recognize and target cancer cells, including those associated with mycosis fungoides. For instance, in September 2022, CRISPR Therapeutics AG, a Switzerland-based biotech company, announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130, the company’s allogeneic CAR T cell therapy targeting CD70, for treating Mycosis Fungoides and Sézary Syndrome (MF or SS). This designation signifies a significant milestone for the CTX130 program, acknowledging the potential of this cell therapy in treating T-cell lymphomas based on promising clinical data. The RMAT designation is part of a program established under the 21st Century Cures Act to expedite drug development and review processes for genetic therapies intended to treat severe or life-threatening diseases.

In November 2021, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Trillium Therapeutics for approximately $2.22 billion, strengthening its presence in oncology, expanding its hematology portfolio, and gaining access to innovative therapies. Trillium Therapeutics, a U.S.-based immuno-oncology company, focuses on developing treatments for mycosis fungoides.

Major companies operating in the mycosis fungoides treatment market are Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Tocris Bioscience, Viatris Inc., Astellas Pharma Inc., Daiichi Sankyo Company, Takeda Pharmaceutical Company Limited, Bausch Health, Eisai Co. Ltd., Horizon Therapeutics plc, Varian Medical Systems, Kyowa Kirin Co. Ltd., Seattle Genetics Inc., Azurity Pharmaceuticals Inc., Innate Pharma S.A., Helsinn Therapeutics, Jubilant Cadista Pharmaceuticals Inc., Elorac Inc., Soligenix Inc., Ceptaris Therapeutics Inc.

North America was the largest region in the mycosis fungoides treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mycosis fungoides treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mycosis fungoides treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Mycosis fungoides treatment encompasses a range of therapies, medications, and procedures aimed at managing and alleviating symptoms associated with cutaneous T-cell lymphoma, a rare type of non-Hodgkin lymphoma primarily affecting the skin. Treatment approaches typically involve a combination of therapies, including topical medications and systemic treatments such as immunotherapy, tailored to the specific stage and severity of the disease.

The primary types of mycosis fungoides treatment include topical steroids and mechlorethamine. Topical steroids are applied directly to the skin to reduce inflammation and irritation. Other treatment modalities encompass photodynamic therapy, radiation therapy, targeted therapy, and chemotherapy, utilized across various healthcare settings such as hospitals, private clinics, and specialty clinics.

The mycosis fungoides treatment market research report is one of a series of new reports that provides mycosis fungoides treatment market statistics, including mycosis fungoides treatment industry global market size, regional shares, competitors with a mycosis fungoides treatment market share, detailed mycosis fungoides treatment market segments, market trends and opportunities, and any further data you may need to thrive in the mycosis fungoides treatment industry. This mycosis fungoides treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mycosis fungoides treatment market consists of revenues earned by entities by providing services, such as phototherapy, dermatological care, and specialized therapies. The market value includes the value of related services provided by the treatment creators or included within the treatment offering. The mycosis fungoides treatment market also includes sales of oral retinoids, interferons, monoclonal antibodies, and nitrogen mustard. Values in this market are ‘factory gate’ values, that is, the value of treatments sold by the manufacturers or creators of the treatments, whether to other entities (including downstream healthcare providers and pharmacies) or directly to end customers. The value of treatments in this market includes related services sold by the creators of the treatments.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.